LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | PF431396 | 1.11 | uM | LJP5 | 72 | hr | 1334 | 1342 | 3970 | 0.3381 | 0.0030 |
| BT-20 | PF477736 | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3744 | 3970 | 0.9429 | 0.9139 |
| BT-20 | PF562271 | 1.11 | uM | LJP6 | 72 | hr | 1334 | 3147 | 3970 | 0.7926 | 0.6876 |
| BT-20 | PHA-665752 | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3851 | 3970 | 0.9700 | 0.9548 |
| BT-20 | PHA-793887 | 1.11 | uM | LJP6 | 72 | hr | 1334 | 1841 | 3970 | 0.4637 | 0.1922 |
| BT-20 | PI103 | 1.11 | uM | LJP6 | 72 | hr | 1334 | 2003 | 3970 | 0.5044 | 0.2535 |
| BT-20 | PLX-4720 | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3897 | 3970 | 0.9816 | 0.9722 |
| BT-20 | QL-X-138 | 1.11 | uM | LJP6 | 72 | hr | 1334 | 3123 | 3970 | 0.7866 | 0.6785 |
| BT-20 | QL-XII-47 | 1.11 | uM | LJP6 | 72 | hr | 1334 | 2040 | 3970 | 0.5139 | 0.2678 |
| BT-20 | Radicicol | 1.11 | uM | LJP5 | 72 | hr | 1334 | 953 | 3970 | 0.2401 | -0.1447 |
| BT-20 | Radicicol | 1.11 | uM | LJP6 | 72 | hr | 1334 | 974 | 3970 | 0.2455 | -0.1366 |
| BT-20 | Seliciclib | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3827 | 3970 | 0.9638 | 0.9454 |
| BT-20 | Ruxolitinib | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3996 | 3970 | 1.0063 | 1.0095 |
| BT-20 | XL147 | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3794 | 3970 | 0.9556 | 0.9332 |
| BT-20 | Saracatinib | 1.11 | uM | LJP6 | 72 | hr | 1334 | 3485 | 3970 | 0.8778 | 0.8159 |
| BT-20 | Selumetinib | 1.11 | uM | LJP6 | 72 | hr | 1334 | 3880 | 3970 | 0.9771 | 0.9655 |
| BT-20 | Sirolimus | 1.11 | uM | LJP6 | 72 | hr | 1334 | 2459 | 3970 | 0.6193 | 0.4266 |
| BT-20 | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 1334 | 3576 | 3970 | 0.9007 | 0.8505 |
| BT-20 | SU11274 | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3767 | 3970 | 0.9487 | 0.9227 |
| BT-20 | Fedratinib | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3561 | 3970 | 0.8969 | 0.8446 |
| BT-20 | TGX221 | 1.11 | uM | LJP5 | 72 | hr | 1334 | 4075 | 3970 | 1.0263 | 1.0396 |
| BT-20 | Torin1 | 1.11 | uM | LJP6 | 72 | hr | 1334 | 1269 | 3970 | 0.3197 | -0.0247 |
| BT-20 | Torin2 | 1.11 | uM | LJP5 | 72 | hr | 1334 | 801 | 3970 | 0.2019 | -0.2022 |
| BT-20 | Tozasertib | 1.11 | uM | LJP5 | 72 | hr | 1334 | 1003 | 3970 | 0.2526 | -0.1258 |
| BT-20 | Trametinib | 1.11 | uM | LJP5 | 72 | hr | 1334 | 3314 | 3970 | 0.8347 | 0.7509 |